Evidence map›Paper›PMID 27334279›Full record

ArticleDrug delivery and translational research2017

Optimized polyethylenimine (PEI)-based nanoparticles for siRNA delivery, analyzed in vitro and in an ex vivo tumor tissue slice culture model.

Alexander Ewe, Sabrina Höbel, Claudia Heine, Lea Merz, Sonja Kallendrusch, Ingo Bechmann, Felicitas Merz, Heike Franke, Achim Aigner

Abstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 55 citations in OpenAlex.

  1. Review
  2. Review
  3. Target, silence, replace: a review on RNA-based drugs in modern medicine.Frontiers in cell and developmental biology · 2026
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Drug delivery systems for RNA therapeutics.Nature reviews. Genetics · 2022
    Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Alexander EweRudolf-Boehm-Institute for Pharmacology and Toxicology, Clinical Pharmacology, Leipzig University, Haertelstrasse 16 - 18, D-04107, Leipzig, Germany.
Sabrina HöbelRudolf-Boehm-Institute for Pharmacology and Toxicology, Clinical Pharmacology, Leipzig University, Haertelstrasse 16 - 18, D-04107, Leipzig, Germany.
Claudia HeineRudolf-Boehm-Institute for Pharmacology and Toxicology, Leipzig University, Leipzig, Germany.
Lea MerzInstitute of Anatomy, Medical Faculty, Leipzig University, Leipzig, Germany.
Sonja KallendruschInstitute of Anatomy, Medical Faculty, Leipzig University, Leipzig, Germany.
Ingo BechmannInstitute of Anatomy, Medical Faculty, Leipzig University, Leipzig, Germany.
Felicitas MerzInstitute of Anatomy, Medical Faculty, Leipzig University, Leipzig, Germany.
Heike FrankeRudolf-Boehm-Institute for Pharmacology and Toxicology, Leipzig University, Leipzig, Germany.
Achim AignerRudolf-Boehm-Institute for Pharmacology and Toxicology, Clinical Pharmacology, Leipzig University, Haertelstrasse 16 - 18, D-04107, Leipzig, Germany. achim.aigner@medizin.uni-leipzig.de.
Leipzig University · DEGSI Helmholtz Centre for Heavy Ion Research · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The non-viral delivery of small RNA molecules like siRNAs still poses a major bottleneck for their successful application in vivo. This is particularly true with regard to crossing physiological barriers upon systemic administration. We have previously established polyethylenimine (PEI)-based complexes for therapeutic RNA formulation. These nanoplexes mediate full RNA protection against nucleolytic degradation, delivery to target tissues as well as cellular uptake, intracellular release and therapeutic efficacy in preclinical in vivo models. We herein present data on different polyplex modifications for the defined improvement of physicochemical and biological nanoparticle properties and for targeted delivery. (i) By non-covalent modifications of PEI polyplexes with phospholipid liposomes, ternary complexes ("lipopolyplexes") are obtained that combine the favorable features of PEI and lipid systems. Decreased cytotoxicity and highly efficient delivery of siRNA is achieved. Some lipopolyplexes also allow prolonged storage, thus providing formulations with higher stability. (ii) Novel tyrosine modifications of low molecular weight PEI offer further improvement of stability, biocompatibility, and knockdown efficacy of resulting nanoparticles. (iii) For ligand-mediated uptake, the shielding of surface charges is a critical requirement. This is achieved by PEI grafting with polyethylene glycol (PEG), prior to covalent coupling of anti-HER1 antibodies (Erbitux®) as ligand for targeted delivery and uptake. Beyond tumor cell culture, analyses are extended towards tumor slice cultures from tumor xenograft tissues which reflect more realistically the in vivo situation. The determination of siRNA-mediated knockdown of endogenous target genes, i.e., the oncogenic survival factor survivin and the oncogenic receptor tyrosine kinase HER2, reveals nanoparticle penetration and biological efficacy also under intact tissue and stroma conditions.

Indexed as

AnimalsCell LineCell Line, TumorHumansLipidsLuciferasesMice, NudeNanoparticlesPolyethyleneimineRNA, Small InterferingLipidsLuciferasesPolyethyleneimineRNA, Small InterferingKnockdownLipopolyplexesPEG-PEI-Erbitux conjugatesPEI/siRNA complexesPolyethylenimineRNAisiRNATissue slices

Identifiers

PMID27334279
OpenAlexW2460538853

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.